Inflammatory Biomarker Tracking Predicted to Enhance 

Response to 3-D Bio-Printed Therapies

Expands OneTest for Longevity with Chronic Kidney Disease Risk Assessment

GAITHERSBURG, Md., March 24, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. ("20/20"), 20/20 BioLabs (NASDAQ:AIDX), an early market entrant in cutting-edge, AI powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced that it has entered into an exclusive U.S. technology license and access agreement with ROKIT Healthcare Inc. ("ROKIT"), a global innovator in chronic disease prediction and regenerative health technologies. Under the agreement, 20/20 will integrate ROKIT's proprietary chronic kidney disease (CKD) prediction algorithm into the 20/20 Longevity Platform, expanding its suite of biomarker-based disease-risk assessment tools.

Under the agreement, ROKIT agreed to reimburse 20/20 for one-third of mutually agreed sales and marketing expenses in exchange for a running royalty to ROKIT on net sales of the combined product. The companies also anticipate negotiating a separate agreement under which ROKIT may receive exclusive rights to commercialize 20/20's longevity platform in Korea and potentially other East Asian markets.

Clinical evidence suggests that patients with lower systemic inflammation, as measured by biomarkers such as CRP, the centerpiece of OneTest for Longevity, tend to experience more favorable biological responses to regenerative therapies such as ROKIT's 3‑D bio-printed tissue patches for burns, chronic kidney disease and heart failure.